-
FDA Grants Jemperli Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
21 Dec 2024 23:42 GMT
… therapies for gynecologic, colorectal and lung cancers. This proves an important task … FDA's decision to grant BTD. Data from this collaborative …
-
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 gets EMA PRIME designation in relapsed extensive-stage small-cell lung cancer
21 Dec 2024 12:26 GMT
… relapsed extensive-stage small-cell lung cancer (ES-SCLC).
The PRIME … FDA’s decision to grant Breakthrough Therapy Designation in … the 2024 World Conference on Lung Cancer earlier this year. GSK … Pharma for the treatment of lung cancer, sarcoma, head and neck …
-
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
20 Dec 2024 22:00 GMT
… (the “Date of Grant”), the Company approved the grant of inducement stock … stock on the Date of Grant. Each stock option vests over … regarding our non-small cell lung cancer clinical trials); the risk that …
-
Drug-Eluting Beads Bronchial Arterial Chemoembolization Combined with Immunotherapy Resulted in Pathological Complete Response of Squamous Cell Lung Cancer: A Case Report
18 Dec 2024 16:06 GMT
… candidate drug for treating lung cancer. Importantly, epirubicin … bronchial arterial chemoembolization in lung cancer patients with hemoptysis. … pathologic assessment of lung cancer resection specimens after … fmed.2023.1201468
15. Grant C, Hagopian G, …
-
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
17 Dec 2024 13:41 GMT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell …
-
GSK's B7─H3─targeted ADC, GSK'227, receives EMA PRIME designation in relapsed extensive─stage small─cell lung cancer
17 Dec 2024 06:53 GMT
… relapsed extensive-stage small-cell lung cancer (ES-SCLC). The … Administration’s decision to grant Breakthrough Therapy Designation in … 2024 World Conference on Lung Cancer earlier this year. GSK … lung cancer in 2022. SCLC represents 10-15% of all lung cancer …
-
FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC
17 Dec 2024 17:39 GMT
… extensive-stage small cell lung cancer (ES-SCLC)) whose … References
U.S. FDA grants breakthrough therapy designation to Trodelvy … of extensive-stage small cell lung cancer. News Release. Gilead. … of-extensive-stage-small-cell-lung-cancer
Dowlati A, Chiang AC …
-
FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC
17 Dec 2024 17:18 GMT
… extensive-stage small cell lung cancer (ES-SCLC) in … 2024 World Conference on Lung Cancer, the investigator-assessed overall … . U.S. FDA grants breakthrough therapy designation to Trodelvy … extensive-stage small cell lung cancer. News release. Gilead Sciences …
-
The Swedish Cancer and Allergy Fund grants SEK 2.3 million to KI researchers
17 Dec 2024 13:03 GMT
… institutions. Of these, 21 project grants are granted, from SEK 100 … allergies in children.
With the grants, the Cancer and Allergy Fund … diagnosis and targeted treatment of lung tumors and triple-negative breast cancer …
-
Ultrasound-Guided Continuous Rhomboid Intercostal and Sub-Serratus Plane Block Comparison of Thoracoscopic Intercostal Nerve Block After Thoracoscopic Surgery: A Prospective Randomized Controlled Study
21 Dec 2024 06:56 GMT
… did not receive any specific grant from funding agencies in the … complications in elderly patients with lung cancer. Chin J Geriatr. 2019;38 …
About
© 1995-2024